Supplementary Material for: Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT
Maul J.-T.
Djamei V.
Kolios A.G.A.
Meier B.
Czernielewski J.
Jungo P.
Yawalkar N.
Mainetti C.
Laffitte E.
Spehr C.
Anliker M.
Streit M.
Augustin M.
Rustenbach S.
Conrad C.
Hafner J.
Boehncke W.-H.
Borradori L.
Gilliet M.
Itin P.
French L.E.
Häusermann P.
Navarini A.A.
10.6084/m9.figshare.4539853.v1
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Efficacy_and_Survival_of_Systemic_Psoriasis_Treatments_An_Analysis_of_the_Swiss_Registry_SDNTT/4539853
<p><b><i>Background:</i></b> The Swiss psoriasis registry SDNTT (Swiss
Dermatology Network for Targeted Therapies) records the long-term safety
and effectiveness of systemic treatment regimens for psoriasis. <b><i>Patients and Methods:</i></b>
Patients with moderate to severe psoriasis are included in the SDNTT
when treatment with a conventional systemic agent or biologic is
initiated that was not previously used by the respective patient.
Patients are followed over a 5-year period. Clinical data are obtained
every 3-6 months using standardized case report forms. Here, baseline
data and follow-up data for 1 year of patients included from October
2011 until December 2014 were analyzed. <b><i>Results:</i></b> Within 39
months, 323 patients from 7 tertiary dermatology centers in Switzerland
were recruited in the SDNTT; 165 patients received biologics and 158
conventional systemic therapies<i>.</i> Patients treated with biologics
had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6
vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; <i>p</i> ≤ 0.005, <i>p</i> ≤ 0.013, <i>p</i> ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, <i>p</i>
≤ 0.003) compared to patients starting a conventional systemic
treatment. PASI reduction was satisfying in both treatment groups, with
60.6% of patients treated with biologics achieving PASI75 after 1 year
compared to 54.2% of patients receiving conventional systemic drugs
(nonsignificant). On average, the drug survival in patients receiving a
biologic therapy was significantly longer than those receiving
conventional systemic treatments (30.5 vs. 19.2 months, <i>p</i> ≤ 0.001). <b><i>Conclusions:</i></b>
In the real-world setting of a prospective national therapy registry,
the application of current therapeutic guidelines for patients with
moderate to severe psoriasis resulted in a PASI reduction of
approximately 70% within the first year of treatment, but current
therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36%
of patients, respectively, at 1 year, highlighting a gap in efficacy
between selective clinical trials and the real-world setting.</p>
2017-01-11 12:42:24
Psoriasis
Swiss psoriasis registry
Conventional systemic treatment
Biologics